CJC-1295 vs Ipamorelin: two different receptors

The comparison most sources get wrong

CJC-1295 and Ipamorelin are usually presented as two options for the same job, as though a researcher picks one or the other the way you would pick between two brands of the same reagent. That framing hides the single most useful fact about them: they bind different receptors, in different receptor families, identified in different research programmes.

A comparison that starts from the receptor is more informative than one that starts from the shelf. Everything below starts there.

GHRH receptor versus the ghrelin receptor

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone. Its 29-residue sequence corresponds to the biologically active portion of native GHRH, with substitutions introduced to resist enzymatic degradation. It engages the GHRH receptor — the same receptor the endogenous hormone uses.

Ipamorelin is not an analogue of anything in that pathway. It is a synthetic pentapeptide developed as a ghrelin-receptor agonist, binding GHS-R1a, the receptor for the hormone ghrelin. Ghrelin and GHRH are separate signalling molecules with separate receptors, and a compound engaging one is not a variant of a compound engaging the other.

This is why the two are frequently studied together in the literature rather than against each other: two different receptors are two different experimental variables, and the interesting questions in that literature concern what happens when each is engaged, not which one wins.

Size, and what it does to your arithmetic

Ipamorelin is one of the smallest peptides in this catalog and CJC-1295 is a mid-sized one, so a milligram of each is a very different number of molecules. The ratio is roughly 4.7 to 1. Any reasoning that treats the two vials as equivalent because they carry the same mass label is off by that factor before it starts.

Size has a second, quieter consequence. Short peptides adsorb to glass and plastic less readily than long ones, so at low concentrations the fraction of material lost to the container walls is generally smaller for Ipamorelin than for a 29-residue peptide. Neither compound is immune, and the effect grows as concentration falls.

The DAC distinction is not a formulation detail

CJC-1295 is sold in two chemically different forms and the difference is routinely flattened in supplier copy. The DAC version carries a Drug Affinity Complex — a maleimide modification that binds covalently to serum albumin, dramatically extending how long the peptide persists in circulation. The version without DAC is the unmodified 29-residue sequence, which is why it is also sold as modified GRF(1-29).

These are not two grades of one product. They have different molecular weights, different circulating behaviour in the published work, and different masses on the certificate. If a COA's mass figure does not match the form named on the label, the label and the vial disagree — and the certificate is the side to believe.

Reading each certificate

• ◆CJC-1295 (no DAC): expect a mass near 3367.89 g/mol. A substantially higher figure suggests the DAC-modified form; a lower one suggests a truncated sequence.
• ◆Ipamorelin: expect a mass near 711.85 g/mol. At this size the mass-spectrometry result is unambiguous — a short peptide either matches or is a different molecule, with little room for interpretation.
• ◆Both: HPLC purity above 98% is the ordinary expectation for synthetic peptides of these lengths. A short peptide like Ipamorelin is easier to synthesise cleanly, so a low purity figure on a pentapeptide is a more serious signal than the same figure on a 43-residue peptide.
• ◆Both: confirm the certificate names the lot on your vial, and that a third-party laboratory — not the synthesis facility — issued it.

Why they are sold as a pair

The two are commonly offered as a blend, and here the pairing has a clearer rationale than most: two different receptors is exactly the kind of combination a researcher might want to examine together. That is a reason the pairing is interesting, not evidence that the combination has been characterised.

The same caution applies as to any blend. Two molecules in one vial means one certificate has to establish identity and purity for both, and a single purity percentage that does not say which molecule it describes has not done that. Separate vials give you two certificates and the ability to vary one thing at a time, which is usually the point of an experiment.

Evidence status

Neither compound is approved for human use in the United States. Ipamorelin was studied in clinical trials that did not lead to approval; CJC-1295's literature is preclinical and early-phase. Both remain research compounds, and the fact that a well-characterised receptor sits behind each one says something about the mechanism, not about safety or effect in any organism.